5278-40-0

Basic information

• Product Name: 3-Quinolinecarboxylic acid, 6,7-dimethoxy-
• Synonyms: carboxylic acid;6,7-Dimethoxy-3-quinolinecarboxylic acid;6,7-dimethoxy-quinoline-3-carboxylic acid
• CAS NO: 5278-40-0
• Molecular Formula: C12H11NO4
• Molecular Weight: 233.224
• Mol File: 5278-40-0.mol
• Article Data: 3

Chemical Properties

• Melting Point: 262 °C (water)
• CAS DataBase Reference: 3-Quinolinecarboxylic acid, 6,7-dimethoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Quinolinecarboxylic acid, 6,7-dimethoxy-(5278-40-0)
• EPA Substance Registry System: 3-Quinolinecarboxylic acid, 6,7-dimethoxy-(5278-40-0)

Safety Data

• Hazardous Substances Data: 5278-40-0(Hazardous Substances Data)

Upstream product

• 209521-75-5 6,7-dimethoxyquinoline-3-carbonitrile 

Downstream Products

• 181514-87-4 6,7-dimethoxy-N-<2-(3,4-dimethoxyphenyl)ethyl>-N-methyl-3-quinolinecarboxamide 
• 181514-91-0 1,2,3,4-tetrahydro-6,7-dimethoxy-N-<2-(3,4-dimethoxyphenyl)ethyl>-N-methyl-3-quinolinemethanamine 
• 850352-74-8 6,7-Dimethoxy-3-((R)-toluene-4-sulfinyl)-quinoline 
• 850352-73-7 3-bromo-6,7-dimethoxyquinoline 

Relevant articles and documents

Synthesis, radiosynthesis and biological evaluation of 1,4-dihydroquinoline derivatives as new carriers for specific brain delivery

In spite of numerous reports dealing with the use of 1,4-dihydropyridines as carriers to deliver biological active compounds to the brain, this chemical delivery system (CDS) suffers from poor stability of the 1,4-dihydropyridine derivatives towards oxidation and hydration reactions seriously limiting further investigations in vivo. In an attempt to overcome these limitations, we report herein the first biological evaluation of more stable annellated NADH models in the quinoline series as relevant neuroactive drug-carrier candidates. The radiolabeled 1,4-dihydroquinoline [11C]1a was prepared to be subsequently peripherally injected in rats. The injected animals were sacrificed and brains were collected. The radioactivity measured in rat brain indicated a rapid penetration of the carrier [11C]1a into the CNS. HPLC analysis of brain homogenates showed that oxidation of [11C]1a into the corresponding quinolinium salt [11C]4a was completed in less than 5 min. An in vivo evaluation in mice is also reported to illustrate the potential of such 1,4-dihydroquinoline derivatives to transport a neuroactive drug in the CNS. For this purpose, γ-aminobutyric acid (GABA), well known to poorly cross the brain blood barrier (BBB) was connected to this 1,4-dihydroquinoline- type carrier. After i.p. injection of 1,4-dihydroquinoline-GABA derivative 1b in mice, a significant alteration of locomotor activity (LMA) was observed presumably resulting from an enhancement of central GABAergic activity. These encouraging results give strong evidence for the capacity of carrier-GABA derivative 1b to cross the BBB and exert a pharmacological effect on the CNS. This study paves the way for further progress in designing new redox chemical delivery systems.

HETEROCYCLIC HYDRAZIDE DERIVATIVES OF MONOCYCLIC BETA-LACTAM ANTIBIOTICS

Antibacterial activity has been found in compounds of the formula. Compounds having the formula and pharmaceutically acceptable salts thereof, wherein: A is a bond or alkylene; Q completes a 5- or 6-membered saturated or unsaturated(including aromatic) heterocyclic ring having one or two, hetero atoms in the ring selected from nitrogen sulfur or oxygen; X is attached to an available carbon atom in the heterocyclic ring and is hydrogen or oxo; Y is attached to an available carbon atom in the heterocyclic ring and is hydrogen, amino, hydroxyl, halogen, carboxamide, nitrile, or carboxyl, except that Y is not carboxyl when the bicyclic ring completed by Q is 2-quinolyl, 3-quinolyl, or quinoxalyl; and the remaining symbols are as defined in the specification